CHDN
Q4 2026 EPS Estimate
$1.21
Oct 28, 2026 · Reports after close
Revenue Estimate
$701M
FY2026E EPS$6.95
FY2027E EPS$7.38

Analyst Sentiment

Wall St. Consensus
Buy
22 analysts·High coverage
75
Score
22 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
22100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$145.00
+54.7%
Consensus
$145.00
+54.7%
Bull
$145.00
+54.7%
12-Month Target Range22 analysts
$145.00$145.00$145.00
Current $93.71Consensus
Current Price
$93.71
Upside to Consensus
$51.29

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev+2.98%
EPS+6.27%
FY2028
Rev+2.90%
EPS+10.69%
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028E
Revenue Avg$3.03B$3.12B$3.21B
Low$3.02B$3.09B$3.16B
High$3.04B$3.13B$3.25B
EBITDA Avg$1.20B$1.24B$1.27B
Low$1.20B$1.23B$1.25B
High$1.20B$1.24B$1.29B
EBIT Avg$982M$1.01B$1.04B
Low$979M$1.00B$1.02B
High$985M$1.01B$1.06B
Net Income Avg$498M$528M$582M
Low$488M$517M$561M
High$508M$539M$605M
EPS Avg$6.95$7.38$8.17
Low$6.83$7.24$7.86
High$7.12$7.54$8.48
Analysts (Rev / EPS)8 / 58 / 56 / 2
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027Q1 2028Q2 2028
Revenue Avg$701M$679M$676M$1.00B$734M$714M$705M$1.04B
Low$699M$674M$670M$994M$727M$707M$698M$1.03B
High$704M$683M$687M$1.02B$746M$725M$716M$1.05B
EBITDA Avg$278M$269M$268M$398M$291M$283M$280M$411M
Low$277M$267M$266M$395M$289M$281M$277M$407M
High$279M$271M$272M$404M$296M$288M$284M$418M
EBIT Avg$227M$220M$219M$326M$238M$232M$229M$336M
Low$227M$219M$217M$323M$236M$229M$227M$333M
High$228M$222M$223M$331M$242M$235M$232M$341M
Net Income Avg$85M$76M$83M$261M$88M$83M$100M$272M
Low$82M$76M$82M$258M$87M$82M$99M$269M
High$91M$77M$84M$266M$89M$85M$102M$278M
EPS Avg$1.21$1.09$1.18$3.73$1.25$1.19$1.43$3.89
Low$1.17$1.08$1.17$3.69$1.24$1.18$1.41$3.84
High$1.29$1.10$1.21$3.81$1.28$1.21$1.46$3.97
Analysts (Rev / EPS)7 / 57 / 53 / 33 / 33 / 36 / 35 / 44 / 4

Earnings Surprises

Recent Analyst Actions

Jun 12, 2026Truist Financial
Truist Reiterates Buy Rating on Churchill Downs (CHDN) After Management Meetings
Target:$145.00
+66.9%from $86.88
Oct 24, 2024Stifel Nicolaus
Stifel Reiterates Buy Rating on Churchill Downs (CHDN)
Target:$164.00
+22.3%from $134.13
Oct 22, 2024Mizuho Securities
Churchill Downs price target lowered to $151 from $157 at Mizuho
Target:$151.00
+11.4%from $135.49
Aug 12, 2024Bank of America Securities
Churchill Downs upgraded to Buy from Neutral at BofA
Target:$155.00
+16.0%from $133.66
Jul 29, 2024Jefferies
Churchill Downs (CHDN) PT Raised to $167 at Jefferies
Target:$167.00
+15.5%from $144.64
Jul 26, 2024Mizuho Securities
Churchill Downs price target raised to $157 from $143 at Mizuho
Target:$157.00
+11.6%from $140.68
Jul 22, 2024Stifel Nicolaus
Churchill Downs (CHDN) PT Raised to $160 at Stifel
Target:$160.00
+14.2%from $140.11
Jul 18, 2024Truist Financial
Churchill Downs price target raised to $165 from $145 at Truist
Target:$165.00
+15.4%from $143.04
Apr 15, 2024Wells Fargo
Wells Fargo Upgrades Churchill Downs (CHDN) to Overweight
Target:$141.00
+16.8%from $120.73
Oct 3, 2023Stifel Nicolaus
Churchill Downs Analyst Sized Up 'High-Quality Kentucky Derby Asset': Project Pipeline Includes Casinos
Target:$148.00
+29.1%from $114.61
Aug 21, 2023JMP Securities
Kentucky's Gaming Revolution: How Churchill Downs Is Pioneering A Stable Growth Pathway With Electronic HHR Table Games
Target:$155.00
+25.0%from $124.03
Dec 14, 2022Wells Fargo
Wells Fargo Maintains Overweight on Churchill Downs, Lowers Price Target to $260
Target:$260.00
+361.1%from $56.39
Dec 8, 2022J.P. Morgan
JP Morgan Initiates Coverage On Churchill Downs with Neutral Rating, Announces Price Target of $243
Target:$243.00
+339.0%from $55.36
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.